Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say

While recent case law that appears to give industry more leverage in off-label communications involves drugs, the precedent should apply equally to devices, attorneys say. Nonetheless, companies should be cautious about moving full-steam ahead with off-label promotions

More from Archive

More from Medtech Insight